Previous studies reported that several signaling pathways, including PI3K/AKT, MEK/ERK, and STAT3, are essential for survival and/or resistance to ALK inhibitors in ALK-rearranged NSCLC cells [12, 32]. This evidence concerns the gene MAPK1 and non-small cell lung carcinoma.